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Abstract
The development of therapeutic proteins and peptides is an expensive and time-intensive process.
Biologics, which have become a multi-billion dollar industry, are chemically complex products
that require constant observation during each stage of development and production. Post-
translational modifications along with chemical and physical degradation from oxidation,
deamidation, and aggregation, lead to high levels of heterogeneity that affect drug quality and
efficacy. The various separation modes of capillary electrophoresis (CE) are commonly utilized to
perform quality control and assess protein heterogeneity. This review attempts to highlight the
most recent developments and applications of CE separation techniques for the characterization of
protein and peptide therapeutics by focusing on papers accepted for publication in the in the two-
year period between January 2012 and December 2013. The separation principles and
technological advances of CE, capillary gel electrophoresis, capillary isoelectric focusing,
capillary electrochromatography and CE-mass spectrometry are discussed, along with exciting
new applications of these techniques to relevant pharmaceutical issues. Also included is a small
selection of papers on microchip electrophoresis to show the direction this field is moving with
regards to the development of inexpensive and portable analysis systems for on-site, high-
throughput analysis.
1. Introduction
The characterization of protein therapeutics presents a unique analytical challenge due to the
inherent heterogeneity of recombinant protein expression. Even small changes in the
manufacturing process can lead to vastly different active pharmaceutical ingredients.
Additionally, numerous physical and chemical degradation pathways can occur during
manufacturing and storage that compromise protein integrity, leading to a potentially
harmful, unstable product [1]. Thorough characterization of protein therapeutics is necessary
at every step of the research and development process, from drug discovery to lot release.
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Due to the potential complexity of product degradation during preformulation and
formulation studies, additional separation techniques are needed to complement the more
widely used column liquid chromatography (LC) methods. To address this issue, capillary
electrophoresis (CE) has become a popular choice for the separation and analysis of
therapeutic proteins and peptides.
CE provides several distinct advantages over LC. First, due to the faster separation times
and the use of multi-capillary arrays, hundreds of samples can be processed by CE per day.
Second, CE is capable of achieving very high efficiency separations due to the low diffusion
coefficients of biomolecules. Lastly, the small dimensions of the capillary and the low
sample volume requirements keep reagent and analyte use to a minimum, reducing the cost-
per-test. The benefits of CE for the analysis of therapeutic peptides and proteins have been
addressed in several excellent reviews to date [2–5].
This review is aimed at highlighting the advances made in the field of CE therapeutic
protein analysis during 2012 and 2013 by expanding on a paper that was recently published
by Zhao et al. [5]. Following brief descriptions of the working principles of the different CE
separation and detection methods, the recent technological improvements and novel
applications are discussed. Two additional sections have been included to further explore the
use of CE for the determination of protein glycosylation and the comparison of biosimilars.
Finally, a brief introduction into microfluidic approaches to protein analysis is given.
Microchip electrophoresis (ME) has the additional advantages of increased speed, high-
throughput capabilities, and portability for on-site analyses. Tables are presented in each
section to highlight the relevant CE and ME application-based citations.
2. Techniques
Historically, capillary zone electrophoresis (CZE) has been the most commonly employed
form of CE. Yet, the principles of electrophoretic separations and the benefits of capillary-
based techniques are applicable to other CE separation modes as well. Protein analysis based
on size can be accomplished by capillary gel electrophoresis (CGE), capillary isoelectric
focusing (CIEF) can be used to determine isoelectric points and charge heterogeneity, and
capillary electrochromatography (CEC), which combines the high efficiency electrophoretic
separation with chromatographic retention, can be used for more selective separations and
analysis of neutral species. Depending on the properties of the analyte and requirements of
the assay, each of these separation modes can be coupled to a number of detection methods
such as UV-Vis absorbance, laser-induced fluorescence (LIF), and mass spectrometry (MS).
2.1 Capillary zone electrophoresis
Of the electrophoresis-based separation techniques, CZE is most frequently used for the
analysis of small molecules, carbohydrates, and peptides. It is simple, easy-to-use, and
requires minimal reagents compared to chromatographic methods. Additionally, in CZE, the
separation of analytes is based on their size-to-charge ratio making it well suited for
separations of proteins with post-translational modifications (PTMs) or degradations that
affect the charge of the molecule [6, 7] including deamidation, glycosylation, and
phosphorylation.
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One example of the use of CZE for the investigation of deamidation concerns the stability of
oxytocin. Deamidation of Asn and Gln residues is the most common chemical degradation
pathway for peptides and proteins [1]. This process leads to the production of an ionizable
carboxylic acid from the neutral amide (R-CONH2 → R-COOH), facilitating a separation by
CZE. However, if peptides, such as oxytocin, contain several labile Asn and Gln sites,
multiple degradation products of the same size-to-charge ratio are produced and a
straightforward separation becomes impossible. To distinguish between the seven desamino
degradation products of heat-stressed oxytocin, Creamer et al. utilized sulfobutyl ether β-
cyclodextrin (SBE β-CD) as a pseudo-stationary phase [8]. The negatively charged SBE β-
CD forms an inclusion complex with the hydrophobic Tyr2 residue of oxytocin, affecting the
electrophoretic mobility of the peptides. A baseline separation of all eight peptides and a
migration time RSD of less than 1.2% was achieved.
Unfortunately, reproducible separations of larger biomolecules using bare fused-silica
capillaries are rare due to protein adsorption. Many proteins have large localized regions of
positive charge that are electrostatically attracted to the negatively charged silanol groups at
the capillary surface. Additional adsorption can be caused by hydrophobic and hydrogen
bonding interactions. This adsorption process keeps CZE from obtaining the 106 theoretical
plates that should be possible due to the very low diffusion coefficients of large proteins. [9,
10].
One strategy for minimizing protein adsorption is to alter either the charge density of the
protein or the capillary wall by changing the pH or ionic strength of the background
electrolyte (BGE). Another approach is to simply add a modifier to the BGE to reduce
protein-wall interactions. The addition of surfactants, small amines, or anionic salts, such as
phytic acid, to the BGE is common [11, 12]. In cases where modification of the run buffer
does not obviate protein adsorption, dynamic and static capillary coatings have been used to
create a barrier between the ionized silanol groups and the protein of interest.
2.1.1 Dynamic coatings—Dynamic coatings are buffer additives that adsorb to the
surface of the capillary, shielding the silanol groups from analyte adsorption [13]. These
noncovalent coatings are popular due to their simplicity, versatility, and ease-of-use.
However, because of their impermanent nature, the coatings need to be continuously
regenerated. This can be accomplished by refreshing the physically adsorbed layer at the
capillary with rinses between runs, or adding a small amount to the BGE to prevent coating
degradation during electrophoresis. A variety of such coatings have been used for protein
separations, ranging from small molecules such as ionic liquids (ILs), to larger molecules
such as surfactants and polymers [14].
ILs have been previously explored as dynamic coatings for CZE protein separations [15–
17]. ILs are salts made up of organic cations and inorganic or organic anions that are liquid
at, or around, room temperature. Recently, a new IL, N-methyl-2-pyrrolidonium methyl
sulfonate ([NMP]+CH3SO3−), was used to prevent basic protein (pI 9.0–10.7) adsorption to
capillary walls during CE separation [18]. The [NMP]+ moiety electrostatically adsorbs to
the capillary surface, where it is able to hydrogen bond for additional stability (Fig. 1).
Using this coating, the authors were able to achieve a baseline separation of four basic
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proteins (Table 1) with an interday migration time RSD of less than 1.5%. The improvement
in the separation after addition of only 0.02% w/v IL, compared to that obtained with
phosphate buffer alone, is easily seen in Fig. 1D.
Polysaccharides are also attractive candidates for dynamic coatings for protein separations
because they are non-toxic, readily abundant, and biocompatible [19–21]. Two novel
dynamic coatings based on the chemical substitutions of cellulose have recently been
reported [22, 23]. The first, a positively charged quaternarnized cellulose (QC), was
synthesized through a reaction of cellulose with 3-chloro-2-
hydroxypropyltrimethylammonium chloride. The positive charge of the QC leads to the
electrostatic adsorption of the compound to the capillary surface, reversing the
electroosmotic flow (EOF). Addition of 5 µg/mL QC to the BGE prevented adsorption of
model basic proteins leading to higher separation efficiencies [22]. To increase the reverse
EOF by 10%, and further improve separation efficiency, additional substitution of the QC
was made using hydrophobic hexadecyl groups [23]. Both QCs were evaluated with a
separation of five basic proteins (Table 1). In both cases, the modified capillaries produced a
migration time reproducibility with RSD of less than 2.7%.
Despite their simplicity, buffer additives and dynamic coatings are not always the best
approach to eliminate protein adsorption. If the modifier is highly charged, band broadening
can occur due to high separation currents and Joule heating. Additionally, some buffer
modifiers can interfere with protein binding assays [24], disrupt protein stability [25], or be
incompatible with downstream detection methods such as MS. In cases where greater
stability and reproducibility are needed, static coatings have been used [13].
2.1.2 Static coatings—Static coatings are chemically linked to the capillary wall and do
not need to be added to the run buffer to acheive reproducible separations. Therefore they
have the potential for large-scale production and can be made commercial available. Several
companies are already selling coated capillaries for protein separations including GL
Sciences (FunCap®), Target Discovery (UltraTrol™), MicroSOLV (CElixer™), and
Beckman Coulter (eCAP™).
Gassner et al. performed a thorough comparison of both commercially available and lab-
generated static coatings in 2013 [26]. Eight coatings were selected—four positive:
FunCap®-type A, UltraTrol™ HR, Hexadimethrin bromide (polybrene) (PB)-dextran
sulfate-PB, and polyethylenimine; and four neutral: FunCap®-type D, UltraTrol™ LN,
hydroxypropylcellulose, and polyvinyl alcohol (PVA). The coatings were evaluated for the
protein recovery, isoform resolution, and migration time reproducibility of two monoclonal
antibodies (mAbs).
For the positively charged coatings, the separation was run in negative polarity. With these
capillaries it was determined that the slower the EOF, the better the resolution. Yet, while
UltraTrol™ HR had the slowest EOF, it had poor reproducibility (8.9% RSD) and was
discarded from the study. For the neutral coatings run in normal polarity, the largest factor
for protein adsorption was the presence of residual silanol groups. This was apparent by the
fact that some EOF was still generated in the capillary. Of the four neutral coatings in this
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study, both commercial options, FunCap®-type D and UltraTrol™ LN, generated a small
amount of EOF at pH 7.0, indicating that the coating was not uniform and there were still
potential sites for protein adsorption. However, it is important to note that the separation
performance of each coating was highly dependent on the pH and composition of the BGE.
Consequently, care should be taken during method development to fully optimize the BGE
for the selected coating.
Due to the varied performance of the commercially available products, new coatings for the
separation of basic and hydrophobic proteins are still under development. One particularly
attractive choice for static coatings is phospholipid bilayers (PLB) because of the protein
resistant nature of the hydrophobic phosphoylcholine polar headgroup. However, the
limiting factor for these coatings is their poor long-term chemical and physical stability.
This can be remedied by cross-linking the PLB with bis-SorbPC which produces a stabilized
phospholipid bilayer (SPB) at the capillary surface [27]. In a recent report, it was shown that
the SPB produced a stable coating over a pH range from 4.0–9.3 [28]. Over the course of
45-days dry storage the migration time reproducibility for both model proteins (Table 1) was
marginally affected and the overall RSD for the EOF was only changed by 1.1%.
To reduce the preparation time for the preparation of static coated capillaries, self-assembled
bilayers and photoinitiated polymerization can be used. An example of such a process was
described by Yu et al. using a photosensitive diazoresin (DR) in combination with either
PVA [29] or polyethylene glycol (PEG) [30]. After exposure to 365 nm light, both the
DR/PVA and DR/PEG coatings were able to prevent protein adsorption and achieve an
efficient separation of several model basic proteins (Table 1) with a migration time precision
less than 4% RSD.
2.1.3 Evaluation of capillary coating performance—Prior to assay development, the
determination of capillary coating performance is extremely important. A previous
analytical approach to determine protein adsorption in capillaries involves flushing the
capillary with the protein of interest to allow adsorption and then measuring desorption on a
subsequent rinse [31–33]. However, with this method, only irreversibly bound proteins are
measured. As an alternative, de Jong et al. recently developed a more direct method using
pressure-driven flow [34]. Briefly, a plug of sample is pressure injected into a capillary at a
low flow rate (0.5 psi) and the Taylor dispersion of the plug is measured at two different
detection points along the capillary. Based on these measurements, the magnitude of the
protein adsorption can be estimated (Fig. 2).
2.2 Capillary gel electrophoresis
The most commonly used analytical method for size determination, purity assessment, and
quality control of therapeutic recombinant proteins is sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). SDS is used to coat the proteins, resulting
in a uniform negative charge proportional to their size. Under an electric field the proteins
are then separated through a sieving gel matrix, allowing for estimation of protein molecular
weight (MW). However, conventional SDS-PAGE can be time-consuming, tedious, and
yield irreproducible results with limited quantitative abilities [35].
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To improve on this important technique, the CGE equivalent, SDS-CGE, has been
developed and utilized for the determination of size heterogeneity of therapeutic proteins
[36–38]. Here the sieving gel is placed inside the capillary through which the negatively
charged SDS-coated proteins are separated. SDS-CGE has many advantages over SDS-
PAGE, including high efficiency separations, more accurate MW and concentration
determination, and the ability to automate the process for high-throughput analysis.
Shi et al. demonstrated these advantages of SDS-CGE over SDS-PAGE, along with the
improved precision of migration time and peak area, for the analysis of the light chain,
nonglycosylated heavy chain, and heavy chain fragments of a mAb [39]. Using the capillary
format, the authors were able to achieve RSDs of less than 0.5% for migration time and less
than 5% for corrected peak area. However, for quality control of biopharmaceuticals, the
precision for a quantitative assay needs to be lower than 2% RSD. By switching from
hydrodynamic rather than electrokinetic injection, along with increased sample
concentration, the precision of a standard SDS-CGE assay was improved to 0.2% RSD for
migration time and between 1 and 2% RSD for peak area ratio [40].
Another method to improve assay precision for the SDS-CGE assay is through automation
of the sample preparation process. A large number of samples are generated during the
development of high-quality biologics. These samples originate from every step of the
development process and are presented for analysis in a variety of matrices. The use of an
automatic robotic platform for sample preparation can help mitigate user error introduced in
the multi-step sample preparation process. The PhyNexus Micro-Extractor Automated
Instrument uses a ProA resin column to bind mAb samples prior to separation. Once bound,
the instrument performs sample concentration normalization, removal of contaminates,
desalting, and mixing with appropriate SDS-CGE buffers. With this method, protein
recovery of Fc-fusion proteins, and IgG1 and IgG2 mAbs was increased to 90% [41].
UV absorbance and LIF spectroscopy are the dominant detection methods for SDS-CGE.
However, for detection of specific mAbs, Western blot immunoassay detection has also
been utilized. The ProteinSimple Simple Western™ (or Simon™) automates the
immunoassay detection procedure by performing all separation steps and washes in-
capillary. Following a SDS-CGE separation, the proteins are photochemically cross-linked
to the capillary wall, where they are exposed to a horseradish peroxidase-conjugated
secondary antibody for whole-capillary chemiluminescence imaging (Fig. 3). Simon™ also
makes quantitative Western blots possible. Using this instrument, a standard curve was
generated for a vaccine candidate protein with linearity from 0.45–7 µg/mL and R2 values of
0.990 or greater for five experiments [42].
Immunoassay detection methods for CGE are useful because coupling CGE with MS by
electrospray ionization (ESI) is difficult due to the presence of nonvolatile BGE. However,
CGE-SDS has been coupled successfully to matrix-assisted laser desorption ionization
(MALDI) MS by moving a poly(tetrafluoroethylene) membrane past the end of the capillary
to collect the peaks as they leave the capillary [43]. CGE-MALDI-MS has been utilized for
the direct mass measurement of recombinant proteins [44, 45] and neoglycoproteins [46].
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2.3 Capillary isoelectric focusing
Another capillary-based technique that was adapted from its original slab-gel format is
capillary isoelectric focusing (CIEF). Like SDS-CGE, performing IEF in a capillary exhibits
the benefits of faster analysis times, higher resolutions (up to 0.005 pH units [47]), lower
limits of detection, and the capacity for high-throughput analysis [48].
CIEF separates proteins based on their isoelectric point (pI) and can be used to determine
charge heterogeneity of biogenic products [49]. The assay is typically performed in a coated
capillary to eliminate EOF. A pH gradient is self-assembled under an electric field using a
mixture of mobile carrier ampholytes with a distribution of pIs. The anodic end of the
capillary is then placed in an acidic solution and the cathodic end in a basic solution. Under
the applied electric field, the protein will migrate through the ampholyte solution toward the
oppositely charged electrode until the pH environment equals its pI.
UV detection at 280 nm is typically used with CIEF because the ampholytes exhibit strong
absorbance at wavelengths below 240 nm [50]. Optical detection for CIEF can be
accomplished either by a two-step method that requires mobilization after focusing to bring
the analyte bands past a small detection window or using whole-capillary imaging CIEF
(iCIEF) within a transparent capillary.
An important application of CIEF for the analysis of biologics is for the characterization of
charge heterogeneity, as it is possible to identify proteins based on their unique charge
profile [51]. Variations in this charge profile are often used to determine protein stability
[52, 53] and identify degradation products or PTMs that change the charge of the protein,
such as glycosylation and deamidation [54].
As mentioned earlier, deamindation can be a major pathway of protein and peptide
degradataion. The rate of deamidation depends on both the primary and secondary structure
surrounding the Asn or Gln residue in question [1]. Typically characterization of
deamidation sites is accomplished through peptide mapping and MS analysis. However, this
process can be complicated, sometimes impossible when a fragment contains multiple
desamino sites. Shimura et al. used CIEF and site-directed mutagenesis to determine the
rates of deamidation in Fab fragments of mouse IgG1-κ [54]. The rate of disappearance of
the parent peak of each mutant was compared to that of the wild type to obtain the single-
residue deamidation rates. By monitoring the CIEF charge profile of the six Fab mutants for
the additional acidic peaks, a third, previously unknown deamidation hotspot for the mouse
IgG1-κ was identified.
CIEF can be even more powerful when run in combination with an orthogonal separation
technique such as SDS-CGE [55] or reversed-phase LC, or in tandem with MS. CIEF has
been coupled to MS through both ESI [56, 57] and MALDI interfaces [58, 59]. Due to the
presence of the non-volatile ampholytes in the separation buffer, coupling CIEF with ESI
can be complicated by ion-suppression and source contamination. To cut down on the
intensive sample preparation needed to desalt protein samples from gels, a segmented
capillary has been described. In this design, seven segments of PEEK capillary were
connected by Nafion joints, each with its own buffer reservoir (Fig. 4) [60]. This allowed
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analytes in the capillary segments to be selectively mobilized after focusing, creating an
online fractionator prior to additional analysis by LC, CE, or MS.
Additional technological advances in CIEF-MS interface development have been reported
by Zhong et al. [61] and Wang et al. [62]. Their work is discussed further in the MS
detection section of this review. Along with the development of new interfaces, several
straightforward BGE buffer modifications have been described in the literature to solve the
problems of high backgrounds and ion suppression [63, 64].
As with SDS-CGE, detection of proteins by immunoassay following separation by CIEF can
be used to improve detection limits and specificity without the need for an MS. For example,
Michels et al. have described the first multiplexed iCIEF immunoassay for investigation of
the charge heterogeneity of mAbs [65]. Once the mAbs were focused, they were then
photochemically immobilized to the capillary wall where they were then exposed to a
secondary antibody, conjugated with horseradish peroxidase, and detected by
chemiluminescence (Fig. 5). The resulting LOD of this assay was 6 ng/mL, which was a
1000-fold increase over UV detection.
2.4 Capillary electrochromatography
Capillary electrochromatography (CEC) is a technique that uses both chromatographic
retention and electrophoretic migration for the separation of analytes, with bulk fluid flow
created by the EOF. This combination enhances the selectivity and efficiency of the
separation, drastically lowers the reagent use compared to LC, and enables the separation of
neutral species not possible with CZE.
In the first applications of CEC to proteins, capillaries packed with porous particles were
utilized because of their similarity to the stationary phase materials used for conventional
LC, and the commercial availability of particles with a variety of functionalities. However,
the packed CEC columns have significant limitations in terms of stability and fabrication
reproducibility and are not yet able to match the robust performance of nano-LC [66]. This
limits their usefulness for routine protein assays on a larger industrial scale. In its place, the
use of nanoparticles (NP) as a pseudostationary phase (PSP), open-tubular CEC (OTCEC),
and monolithic columns have gained momentum.
The use of NP as a PSP for CEC has been thoroughly reviewed [67]. In the BGE, the NP can
interact with the proteins during the separation, changing their electrophoretic mobility and
generating a separation based on the difference in affinity between the analytes for the NP.
A wide range of materials have been investigated for PSP-CEC, including polymer NP,
carbon nanotubes, gold NP, and silica NP (SNP) [67]. To improve the stability and
functionality of SNP, Gao et al. synthesized polyamidoamine-grafted SNP (PAMAM-SNP)
and utilized them for a separation of basic and acidic proteins [68] (Fig. 6). With 0.01%
PAMAM-SNP in the BGE, a complete separation of all four model proteins (Table 4) was
possible. Additionally, the PAMAM-SNP were able to effectively reduce the adsorption of
basic proteins to the capillary wall.
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OTCEC columns are a popular alternative to packed columns because of their ease of
fabrication and excellent separation efficiency [69]. These OTCEC columns can be made by
either physically bonding the stationary phase to the capillary wall or several layered
coatings. In one report, OTCEC columns were fabricated through the immobilization of gold
NP (AuNP) on the surface of the capillary that had been pretreated with a sol-gel. The gold
immobilized in the sol-gel participates in noncovalent interactions with thiol and amino
groups of proteins, increasing their capacity factor. Using this technique, Miksik et al. were
able to separate the peptides generated by the tryptic digestion of native and glycosylated
bovine serum albumin (BSA) and human transferrin [70]. Unfortunately, preparation of the
AuNP modified columns required several days and many reaction steps, which limited its
utility. To alleviate this problem, a new method for AuNP immobilization to the capillary
wall through covalent binding using (3-aminopropyl) triethoxysilane has been described
[71]. This procedure creates a stable coating that could be reused over 900 times with
migration time RSDs less than 1.7% for model proteins (Table 4).
Another novel OTCEC column was described by Qu et al. and was produced by
immobilizing graphene (G) and graphene oxide (GO) sheets to the capillary wall to act as
the stationary phase. It was found that between the two coatings, only the GO exhibited a
reproducible EOF over the pH range of 3–9 and separate a mixture of egg white proteins
[72]. The separation was achieved due to the reverse-phase-like interaction between the
graphene coated surface and the proteins. To improve the stacking of GO at the capillary
wall, a layer-by-layer technique to produce the GO-modified OTCEC column was reported.
In this case, GO nanosheets were adsorbed on a poly(diallydimethylammonium chloride)-
treated capillary by electrostatic interaction. This created a stable coating for over 200 runs
[73]. Both methods for column fabrication produced excellent run-to-run, day-to-day, and
column-to-column reproducibility with less than 3% RSD for the EOF.
Often, OTCEC separations suffer from low capacity factors because of the small active
surface area and fewer available functional sites. This also can lead to poor separation
efficiency and co-eluting peaks. In an attempt to improve peak capacity, a new porous layer
for OTCEC has been described that uses the in situ polymerization of a mixture of
monomers in the presence of porogen for higher separation efficiencies [74]. A column
generated from the porogen, 1-propanol, was able to generate a high abundance of
micropores and mesopores, resulting in a large specific surface area. This generated an
efficient separation of the two model proteins, BSA and cytochrome-c.
Another widely explored approach for the implementation of CEC is the use of monolithic
columns. Monoliths have high permeability, a fast mass transfer rate, and high loading
capacity. Many commercially available monoliths are made from silica leading to a risk of
band broadening and sample loss due to protein adsorption. Therefore, to minimize protein
adsorption during CEC and improve separation efficiencies, neutral and cationic monoliths
have been developed.
A series of neutral nonpolar monolithic columns were manufactured and tested for the
separation of both intact proteins and peptides from protein tryptic digest. To produce the
monoliths, various ratios of monomers C8-methacrylate, C12-methacrylate, and C16-
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methacrylate were mixed with the crosslinking polymer pentaerythritol (PETA) [75]. In
these experiments, it was determined that when the ratio of monomer to PETA was kept
constant, the C8 monolith gave the best separations for intact proteins. The C16 column
exhibited the best efficiencies for smaller peptides. In their report, Puangpila et al. claim
that, even in the absence of a charged surface, there is EOF generated by adsorption of BGE
ions to the monolith and it can be controlled by changes in the pH and ACN content of the
mobile phase.
Cationic monolithic columns can also be used to reduce electrostatic interaction of basic
proteins to the monolithic and capillary surface. Wang et al. developed a novel monolithic
IL column that was made by a simple “one pot” approach using thermal free radical
copolymerization [76]. Using this method, several counterions (bromide, tetrafluoroborate,
hexafluorophosphate, and bis-trifluoromethanesulfonylimide (NTf2−)) were tested with the
cation 1-vinyl-3-octylimidazolium (ViOcIm+) to create an IL monolith capillary columns
[77]. Each IL monolith was capable of generating a consistent reverse EOF over the pH
range 2.9–12.0. However, only the ViOcIm+NTf2− was able to achieve baseline resolution
for all proteins in a standard mix (Table 4).
3. Detection methods
3.1 Spectroscopic detection
Spectroscopy is the most common detection method for proteins and peptides separated by
CE. UV absorbance tends to be favored over fluorescence spectroscopy due to a natural
absorbance of the amide bonds and aromatic residues in the near UV (214 and 280 nm).
However, this approach suffers from poor limits of detection due to the micrometer
pathlengths characteristic of CE and high background from the UV source. Additionally,
BGE composition, pH, and ionic strength can have a significant effect on background.
Approaches such as increasing the pathlength through modification of the detection window
using Z-shaped capillaries and bubble-cells have been successful in decreasing the LOD by
an order of magnitude or greater [78, 79].
Fluorescence detection of proteins can be accomplished based on the native fluorescence of
tryptophan, phenylalanine, and tyrosine residues in proteins using a deep UV light sources
[80–82]. However, with native fluorescence based detection, the signal is dependent on the
number of excitable residues as well as their accessibility within the tertiary structure of the
protein. Therefore, the applicability of this technique varies from protein to protein. To
improve the LODs for native fluorescence detection of erythropoietin (EPO), Wang et al.
utilized a magnetic bead-based extraction system for pre-concentration. Using this
procedure, it was possible to obtain an LOD of 10 nM, two orders of magnitude lower than
what was possible with UV absorbance at 214 nm [83].
Low limits of detection achievable by LIF can also be obtained through derivatization of the
protein or peptide of interest with a fluorophore [84]. The most common derivatization sites
for proteins are the primary amines and cysteine residues. These can be tagged with a
variety of agents including Alexa Fluor-based dyes, naphthalene-2,3-dicarboxaldehyde,
fluoresceinisothiocyanate, and many others. A major disadvantage of pre-separation
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derivatization for proteins is the complexity of the derivatization process. This approach
requires not only that the tag is specific for the functional group on the analyte of interest but
also that it does not interfere with the separation by introducing additional fluorescent by-
products. Proteins typically have several reactive sites that can be labeled which leads to
multiple peaks for one analyte, complicating data analysis [85].
3.2 Mass spectrometry
CE-MS is a powerful combination of high efficiency separations with selective and sensitive
detection. This technique can provide important information on identity, glycoforms,
degradation, and impurities of protein therapeutics [86, 87]. It is possible to couple CE to
MS using different ionization techniques, as has been described in several excellent reviews
[88, 89]. For this review, only the recent advances regarding the development and
application of the ESI interfaces will be highlighted. CE was first interfaced with MS by ESI
in 1987 [90] and it remains the most popular ionization method due to its broad applicability
and commercialization.
ESI is a robust soft-ionization technique that produces multiply charged ions for proteins in
the gas phase. However, there are many considerations that must be taken into account when
coupling it with CE. Primarily, the use of run buffers containing non-volatile salts and
additives can lead to their deposition within the instrument, and subsequent contamination of
the source. While formic acid and acetate buffers have been used as BGEs for the separation
of proteins by CE, they are not always ideal because of inadequate resolution and possible
protein instability at low pH. Additionally, the voltages typically applied to the capillary for
separation are 2–3 orders of magnitude higher than what is used for ESI. Toward this end,
researchers have developed three general approaches for coupling CE to MS with ESI:
sheath-liquid, sheathless, or junction-at-the-tip interfaces.
The most widely used and commercially available option is the sheath-liquid interface. This
is accomplished by placing the outlet of the CE capillary coaxially within a tube. The tube
delivers a MS-compatible sheath liquid (Fig. 7A) that provides easy electrical connections
and a flow rate to the ESI of µL/min. This is beneficial because the EOF of the CE is
generally much slower (nL/min) than what is compatible for a stable spray.
The compatibility of separation and detection parameters for CE-ESI-MS with a sheath-
liquid interface was evaluated for eight model proteins and several EPO isoforms [91]. It
was found that the BGE composition and capillary coating play the largest role in the quality
of the separation. For all analytes the best signal was obtained with a sheath flow rate
between 2–5 µL/min and a sheath flow liquid composed of 1% acetic acid in 1:1
organic:water; in this study, 2-propanol was chosen over MeOH or ACN. The optimal gas
pressure was determined to be 0.2 bar, since anything lower lead to a loss of analyte
intensity and anything higher was shown to affect the resolution of the separation. As an
added benefit, the nebulizer gas pressure can create suction at the capillary outlet, increasing
the CE flow rate for separations performed in neutral capillaries.
An obvious disadvantage of the sheath-liquid interface is the loss in detector sensitivity from
dilution of the eluting peaks. To improve detection limits, a sheathless interface was
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developed. The largest downside of this approach is the difficulty in properly completing the
electrical circuits for the CE and the ESI. While many attempts have been made, these
interfaces were limited by stability and ease of application [89, 92].
Recently, Moini and Whitt developed a sheathless interface based on a porous junction [93,
94]. In this interface, the end of the capillary was made porous to small ions by drilling a
well into the polyamide coating and etching the remaining material with hydrofluoric acid.
The capillary was then placed within an existing ESI needle filled with BGE, allowing
electrical connection to both the CE and ESI (Fig. 7B). The tip of the capillary could then be
used for electrospray when voltage is applied. The only drawback to this technique was the
difficulty in reproducibly etching the capillary end. To improve the applicability and
availability of the Moini and Whitt sheathless interface, Beckman Coulter developed a
prototype that has been successfully applied to the analysis of intact proteins [95], protein
glycoforms [96], and protein tryptic digests [97, 98].
In a recent report, both CE- and LC-MS were compared for the analysis of a particular
therapeutic mAb [98]. With LC-MS, 11 small peptides eluted in the void volume and could
not be detected, including two fragments that were critical for the identification of the
binding domain of the mAb. The same digest was analyzed by CE-MS employing both a
traditional sheath-liquid interface and the Beckman Coulter sheathless interface using a BGE
consisting of 10% acetic acid at pH 2.3. Sixty of 61 peptides were detected with the sheath-
liquid interface, while all 61 peptides were detected with the sheathless system with higher
separation efficiencies and better sensitivity.
Another alternative to the sheath-liquid interface is the junction-at-the-tip design developed
by Chen’s group. In this interface, the capillary end is placed within a hollow needle that
forms a “flow-through microvial” [99] (Fig. 7C). The hollow needle is filled with a chemical
modifier that provides the necessary electrical contacts for the separation and ESI voltages.
Similar to a sheath-liquid interface, this modifier increases the CE BGE compatibility with
the ESI. However, because the flow rates are much lower (< 1 µL/min), the dilution factor is
not significant. Chen’s group has extensively characterized the performance of this interface
in several publications [100–102].
Perhaps the most exciting new use of these interfaces is in coupling MS to more complex
CE modes, such as CIEF and capillary isotachophoresis (CITP) which require high
concentrations of non-volatile components to achieve a separation. In 2011, Zhong et al.
described a CIEF-MS approach for the analysis of several model peptides and proteins using
the junction-at-the-tip interface with coated and uncoated capillaries [61]. Unfortunately, the
ampholytes used for the separation were still able to reach the detector, leading to high
backgrounds and ion suppression. To prevent this from occurring, a new sheathless interface
was developed by Wang et al. that uses a large bore separation capillary for sample loading
and a sheathless interface with a porous emitter for its application with CITP [62] (Fig. 7D).
This system was then utilized for the analysis of test peptides spiked into tryptic digests of
BSA (Table 5). They were able to obtain a linear range over 4.5 orders of magnitude and a
five-fold sensitivity improvement compared to the sheath-liquid interface for two test
peptides, kemptide and angiotensin II.
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In addition to assessing protein pharmaceutical products based on their size and charge
heterogeneity and the presence of impurities, the analysis of biologics poses two additional
analytical challenges: 1) how to characterize and better understand the complicated cellular
process of glycosylation, and 2) preparing for the onset of biosimilar drugs to the market and
how to best prove their similarity to the innovator product.
4.1 Glycosylation
Glycosylation is one of the most prevalent PTMs of therapeutic proteins. In vivo,
glycosylation plays several important roles, including protection against degradation and
non-specific interactions as well as orientation for the binding domain. The two major types
of glycosylation that occur involve N-linked and O-linked carbohydrates. N-linked glycans
are attached to the protein backbone at the amine side of Asn and are found in the well-
defined amino acid sequence of Asn-X-Ser/Thr, where X is any amino acid but proline. O-
linked glycans are not sequence-specific and are found attached to the protein backbone at
the OH group of Ser or Thr.
Monoclonal antibody-based therapeutics of the IgG1 sub-type make up a 100 billion dollar
annual market [103]. These mAbs consist of 2–3% carbohydrate by mass. Most of the
glycosylation occurs as N-linked glycans located on the Asp297 in the CH2 domain of the Fc
region of each heavy chain. A number of factors can affect the composition, structure, and
frequency of these glycans, posing an interesting challenge for the manufacturing of a
homogeneous product. To ensure a homogeneous product and avoid potentially
immunogenic glycans, each step of biotherapeutic production from clone selection to lot
release needs to be well characterized. This characterization requires fast, high-throughput
analytical methods to accurately screen the numerous samples generated per day.
The size and charge characterization of glycoproteins can be accomplished by the various
electrophoretic separation techniques mentioned in the previous sections of this review.
Several methods and protocols for CZE, SDS-CE, and CIEF separations of glycoproteins
have been compiled by Rustandi et al. [104]. A typical downside to CE-based methods is the
characteristic migration time irreproducibility. To address this, freely available software,
glyXalign, was developed based on a set of rapid algorithms that enables automatic
correction of distortions in CGE-LIF data to improve peak identification [105].
For further understanding of the nature, location, and composition of the glycans, methods
for the removal and analysis of the sugars themselves are also needed. The majority of these
carbohydrate analyses are performed by LC. In particular, hydrophilic interaction
chromatography (HILIC) coupled to LIF and MS detection has been useful for the sensitive
analysis of glycans [106].
CE-LIF is an excellent orthogonal technique to HILIC-LIF for separation of glycans, and in
a comparative study it was shown that they were able to detect an equal number of glycans
removed from an IgG [107]. An advantage of CE-LIF for glycan analysis is that it can be
used to distinguish both lineage and positional isomers [108, 109]. Using CZE-LIF,
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carbohydrate sequencing can be performed by both top-down digestion and bottom-up
identification using a series of sugar-specific exoglycosidases. Typically, glycans are
enzymatically removed, fluorescently labeled, and separated by size or charge. There are
several charged fluorescent reagents commercially available for tagging glycans. The most
common reagent used in conjunction with CE-LIF is 8-aminopyrene-1,3,6-trisulfonic acid
(APTS). However, recently, Kuo et al. published a rapid method for labeling aldoses with
2,3-naphthalenediamine to produce highly fluorescent naphthimidazole derivatives [110].
Using this reagent, it was possible to perform composition analysis and enantioseparation of
the glycans using CE with cyclodextrin in the BGE.
An important advantage of CE-LIF over HILIC-LIF is the ability to multiplex 48- and 96-
capillary arrays for high-throughput analysis. Callewaert et al. were the first to perform
glycan analysis using a commercially available multiplexed CE-based DNA analyzer [111].
Later, this same technique was used along with a 48-capillary array to perform high-
throughput analysis of glycans from IgG. In this application, glycans were removed by
digestion and labeled with APTS in 96-well plates and then subjected to simultaneous
analysis by capillary array. This approach made it possible to run 3000 samples in a single
day [112].
In the research and development of mAbs, a particular area of interest is the study of
immunogenic non-human glycans. The frequency and type of non-human glycans attached
to the therapeutic protein during production differ from cell line-to-cell line [113]. It is well
known that the non-human oligosaccharides galactose-α-1,3-galactose (α1,3-Gal) and N-
glycolylneuraminic acid (Neu5Gc) can illicit an immune response. In fact, in response to
enteric bacteria, approximately 1% of all human antibodies are against the α1,3-Gal epitope
[114].
Detection of both α1,3-Gal and Neu5Gc non-human glycans was performed by partial
filling affinity CE. In this method, a plug of either anti-Neu5Gc antibody or α-galactosidase
(dissolved in BGE) was injected on capillary prior to injection of the APTS-labeled glycans
(removed from the target antibody) [115]. Once the electric field was applied, the higher
mobility sugars in the sample pass through the antibody or enzyme plug, causing a reaction.
This reaction produced additional product peaks upon LIF detection, allowing specific
detection and quantification of the two immunogenic sugars.
In another study, six commercially available mAb pharmaceuticals produced in nonhuman
mammalian cell lines were analyzed by CZE-LIF, in parallel with LC-ESI-TOF-MS, to
determine the presence of nonhuman N-glycans [116]. By CZE, forty-six fluorescently
labeled N-glycans were separated using a tris-borate BGE containing 5% PEG to slow the
EOF. Of the six mAb pharmaceuticals, three were found to contain nonhuman N-glycan
residues. To obtain additional information regarding the attachment of nonhuman N-glycans
to therapeutic proteins, CZE-LIF with exoglycosidase digestion and fluorescent tagging was
used to achieve LODs of 1 µg allowing characterization of the low-abundance α1,3-Gal
epitope [117].
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CE-MS can also be used in conjunction with CGE-LIF [118] to obtain additional structural
information and identify unknown glycans [2]. For example, Bunz et al. described both
alkaline and acidic BGE systems that could be used for the determination of APTS-labeled
mAb glycans by CE-TOF-MS [119, 120]. The CE-MS methods were then compared against
to two CGE-LIF methods commonly used for routine glycan analysis. While both CE-MS
and CGE-LIF were able to resolve and detect the glycans, because of the difference in the
separation mechanisms they had different migration orders, making it difficult to directly
compare the two electropherograms obtained for a complex sample.
The downside of glycan analysis by MS is the likelihood of unwanted fragmentation of
sugars during the ionization process. This can lead to large amounts of difficult-to-interpret
data and misidentification [121]. For this reason, it is important not only to insure careful
optimization during MS method development but to provide orthogonal analyses such as
CZE-LIF or CGE-LIF to validate the findings.
4.2 Biosimilars
Follow-on biologics, also known as biosimilars or biobetters, is the term for the “generic”
biopharmaceuticals that have recently entered the market. The European Medicines Agency
published regulatory guidelines for biosimilars in 2005, and by 2012 there were 14 products
approved for sale in Europe [122]. In 2013 the first mAb biosimilar, Hospira’s Inflectra, hit
the European market, and more than a half-dozen prospective biosimilars are in the pipeline.
In 2015, as the majority of the leading biologics go off patent, there will be ample
opportunity for established and start-up companies to begin producing biosimilars.
While production of biosimilars is an inherently less risky venture, due to the established
market and tested safety of the innovator product, proving comparability to regulatory
agencies still poses a significant challenge. Unlike chemical synthesis of small molecule
generics, the composition of biologics is highly dependent on the manufacturing process.
Small changes in production can have significant implications on the quality. In particular,
the addition of impurities, aggregation products, and/or PTMs such as glycans can cause the
protein to be immunogenic. Without detailed knowledge of how the innovator was
produced, it can be very difficult to create an identical product.
Fortunately, dozens of analytical techniques exist to verify the physicochemical and
functional comparability of the biosimilar to the innovator [123]. As discussed in the
previous sections of this review, electrophoretic techniques are widely used for
characterization of size and charge heterogeneity, product degradation, and PTMs. The
appropriate method is generally chosen based on protein complexity, which varies from
small non-glycosylated proteins like insulin and HGH to large, heterogeneous glycoproteins
and mAbs [124].
EPO is a glycoprotein with approved biosimilars making up 12% of its market [122]. EPO
has three complex N-glycosylation sites and one O-glycosylation site, which introduce a
high level of heterogeneity into the protein. To be able to differentiate between the various
formulations of EPO, or prove similarity between innovator and biosimilar, Taichrib et al.
evaluated two multivariate statistical approaches for the analysis of CE-MS data [125]. The
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data were generated using a CE-ESI-TOF-MS method developed previously that exhibited
high separation efficiencies and high selectivity for 14 commercially available preparations
of EPO [91]. Both statistical approaches proved useful for analyzing the similarity or
difference between large sets of glycosylated biologics that were generated under different
production conditions, cell lines, and various batch numbers.
With the upcoming mAb biologic patent cliff, much of the biosimilar research has focused
on the comparability of antibodies from various sources. Towards this end, CZE [126] and
SDS-CGE [127] techniques can be used to determine charge heterogeneity of mAbs. Using
CZE, rituximab (Kikuzubam® and Reditux®) and trastuzumab biosimilars were analyzed
with respect to existing commercial products, Mabthera® and Herceptin®, respectively
[126]. The CZE methods were then compared to existing CIEF and chromatographic
methods (HILIC and cation exchange chromatography). They found that, not surprisingly, a
single method was not sufficient to resolve and characterize a protein, putting the emphasis
on orthogonal techniques. However, they did report that CZE and CIEF gave better
resolution of the mAbs than either HILIC and cation exchange chromatography, especially
when using coated capillaries, since protein adsorption tends to lead to band broadening.
With the multitude of assays that exist, reproducibility and ruggedness is essential for
widespread biosimilar production and regulation. The innovator, the biosimilar
manufacturer, and the regulatory agency need to be certain that, despite the various
laboratory conditions, the experimental results are comparable. To help facilitate this, Salas-
Solano et al. evaluated an iCIEF method in 12 different laboratories across the world using
several analysts, a variety of ampholytes, and multiple instruments [128]. The combined
precision for the 12 labs was 0.8% RSD for the pI determination and 11% RSD for the
percent peak area values for the charge variants of a therapeutic mAb. This study compared
these values to those obtained using conventional CIEF, where the RSDs for pI and peak
area were of 0.8% and 5.5%, respectively [129].
5. Microchip electrophoresis
Many aspects of CE, such as low sample volume requirements, speed, efficiency, and the
ability to use physiologically appropriate BGEs, make it an attractive method for the
analysis of biopharmaceuticals. The advantages CE offers over chromatography are a
function of the small inner diameter of the capillary. Consequently there has been an effort
to further miniaturize bench-top CE instrumentation to a microfluidic format. This has
decreased samples sizes needed for analysis from mL to µL, reduced analysis times from
minutes to seconds, increased separation efficiencies, decreased costs, and added the ability
for portable point-of-care analysis. Additionally, multiplex ME systems can be designed to
handle high-throughput analysis on a greater scale than CE systems, making them an
attractive technology for drug discovery and analysis [130, 131].
While most CE separation modes can be transferred to ME, the majority of the current
published assays have dealt with analysis of biomarkers and small molecule drugs. Recent
advances in N-glycan profiling by ME have also been made for clinical chemistry
applications [132–134]. However, as the field of protein analysis on-chip grows, so does the
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possibility that the use of these devices will soon be accepted by the FDA as a validated
method, allowing them to be incorporated into industry protocols.
5.1 Microchip gel electrophoresis
The LabChip® GXII, a commercially available microchip gel electrophoresis (MGE)
system from PerkinElmer, is used frequently in the pharmaceutical industry [135, 136]. The
commercial procedure, which uses indirect fluorescence and a HT Protein Express gel
matrix [137], was compared against two new SDS-MGE methods, one for “high-sensitivity”
and the other for “high-resolution” [138]. In the “high-sensitivity” method, direct LIF
detection of fluorescently labeled proteins was investigated. Two labeling schemes were
compared, and it was reported that performing the labeling step prior to protein denaturation
improved the signal up to 50-fold for a loading concentration LOD of 1 ng/mL. In the “high-
resolution” method, the sieving effect of the commercial gel was increased by the addition
of a 6% poly(N,N-dimethylacrylamide) (PDMA) solution. With an optimal ratio of 2:1,
gel:PDMA, the assay achieved resolution between Fab heterodimers without increasing the
separation time. Additional high-throughput analysis is available to process 96 samples in
less than an hour.
SDS-MGE has also been integrated with Western blot immunoassay detection [139]. The
separation of a series of test proteins with a MW range of 11–155 kDa (Table 2) was
performed on-chip by Jin et al. [140]. Following the separation, the sample was eluted from
the chip onto the Western blot membrane. In order to maintain the discrete zones
accomplished during the separation, the chip was held in place vertically while the
membrane moved below the outlet on an X–Y stage for spotting (Fig. 8). By carefully
controlling the membrane spotting rate and the flow from the SDS-MGE chip, separation
efficiencies of 40,000 theoretical plates were possible. With this set-up, the throughput
capabilities were improved with a total analysis time of less than 32 min for the separation
and immunoassay. This is a dramatic improvement over the traditional Western assay that
takes several hours to complete.
5.2 Microchip isoelectric focusing
ME-based systems have also been used to verify the charge heterogeneity of mAbs with
microchip isoelectric focusing (MIEF). Using a commercially available MCE-2010 system
with whole-channel imaging from Shimadzu, Kinoshita et al. were able to analyze the
charge variants of several mAbs [141]. The microchip consisted of two sample wells, one
containing an anolyte and the second containing a catholyte, separated by a 2.7 cm channel.
Following the separation, the whole channel was imaged with UV detection. To reduce the
EOF, 0.2% hydroxyproplymethylcellulose was added to the BGE allowing greater focusing
while preventing the non-specific adsorption of protein to the capillary wall. Using the
optimized conditions, the authors were able to separate charge variants of three
commercially available mAbs (bevacizumab, trastuzumab, and cetuximab) within 200–300
s. These separations were very reproducible (< 0.5% RSD) and were roughly 10 times faster
than the corresponding CIEF assay.
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To further improve the utility and throughput of MIEF assay a single-channel microchip
device where separation, immobilization, and subsequent immunoblot rinse steps could all
be performed has been reported [142]. Once the proteins were separated within the pH
gradient they were exposed to UV light and covalently cross-linked to a light-activated
volume-accessible gel present in the microchip. This technique gave similar capture
efficiencies (≈ 0.01%) to previous reports where proteins were immobilized on the inner
surface of the capillary [42, 143]. Wash steps were performed by electrophoretic transport
on the immobilized protein without concern of sample loss. Using this technique it was
possible to complete an isoform assay in less than 120 min, up to 15x faster than the
conventional slab-gel followed by Western blot. Such rapid purity assays illustrate the
significant advantage ME has over CE and other techniques.
5.3 Microchip electrophoresis-mass spectrometry
As with CE, even more specific and selective detection of analytes is possible by coupling
ME to MS. The most common ionization interface for ME with MS is ESI, but MALDI is
also possible [144]. The major benefit of ME-ESI-MS is that the flow rate on-chip is
compatible with ESI and can therefore be seamlessly interfaced without disrupting the
electrophoretic separation. When constructing an ME-MS interface, the geometry of the
outlet and flow rate through the capillary must be taken into account given their monolithic
construction and integration.
An advantage of ME over CE is that sample preparation and multiple separation methods
can be integrated onto a single device prior to the ESI interface. Therefore, the excess dead
volumes that are characteristic of conventional systems are eliminated, reducing the band
broadening and sample dilution. The Ramsey group reported a fully integrated LC/CE
microchip that terminated in an ESI source off the corner of the device in 2011 [145]. The
potential combination of LC and ME for a more selective and specific separation is very
powerful. In addition, the microchip flow rates are compatible with the ESI. However, a
major disadvantage of fully integrated microchips is that the increased complexity of the
device makes them difficult to fabricate.
As noted in a subsequent Ramsey paper, the fully integrated chip described above could not
handle pressures over 200 bar. Therefore, to improve on the earlier design, a glass microchip
that could be integrated with an off-chip UPLC was designed (Fig. 9) [146]. This allowed
higher pressures to be reached than were possible with the LC on-chip. The new device
produced significant improvements in reproducibility and peak capacity when evaluated for
the analysis of digested N-glycosylated proteins. Additionally, the authors point out the
utility of the new design in its ability to integrate to existing LC equipment that is already
ubiquitous in industry.
6. Conclusions and future perspectives
The development of protein and peptide therapeutics is a complex and high-risk venture, as
products produced by recombinant expression are inherently heterogeneous. However, with
advances in analytical techniques, thorough protein characterization is possible. In
particular, CE-based separation techniques such as CZE, CGE, CIEF, and CEC provide
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versatile, efficient, and fast analyses of proteins. Additionally, CE-based techniques have the
potential for high-throughput analysis using capillary arrays. The wide range of capillary-
based separations can assess many aspects of protein stability, process impurities, and PTMs
such as glycolysis, each of which is essential in providing a safe, effective, and quality
product.
Microchip based formats have the potential for increased speed, higher throughput, and
portability of CE. While the development of ME devices is still primarily an academic
research area, there is considerable promise for this miniaturized technique in the future of
on-site pharmaceutical analysis. Pharmaceutical applications of ME and CE to therapeutic
protein analysis will be further expanded through the development and commercialization of
specialty capillaries, BGEs, and detection techniques. This is especially true for CE-MS and
ME-MS interfaces. With numerous reviews already existing on this topic alone, coupling of
MS with these techniques show great promise in the future for therapeutic protein analysis.
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BSA bovine serum albumin
CEC capillary electrochromatography
CE capillary electrophoresis
CGE capillary gel electrophoresis
CIEF capillary isoelectric focusing
CITP capillary isotachophoresis
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HILIC hydrophilic interaction chromatography
HPMC hydroxyproplymethylcellulose






MALDI matrix-assisted laser desorption ionization
ME microchip electrophoresis
MGE microchip gel electrophoresis





[NMP]+CH3SO3™ N-methyl-2-pyrrolidonium methyl sulfonate
OTCEC open-tubular capillary electrochromatography
PETA pentaerythritol
PLB phospholipid bilayers




PTMs post translational modifications
PSP pseudostationary phase
QC quaternized celluoses
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SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SNP silica nanoparticles
SDS sodium dodecyl sulfate
SPB stabilized phospholipid bilayer
SBE β-CD sulfobutyl ether β-cyclodextrins
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A) The structure of the IL [NMP]+CH3SO3−, B) the interaction between [NMP]+ and the
silica capillary inner wall , and C) the mechanism of separation of proteins using [NMP]+ as
dynamic coating material, D) Electropherograms of four basic proteins in bare silica
capillary (bottom trace) and in the presence of 0.02% w/v IL (top trace). Running buffer: 40
mM pH 4.0 sodium phosphate; voltage: 18 kV; detection: 214 nm; peaks: (1) cytochrome c,
(2) lysozyme, (3) ribonuclease A, (4) α-chymotrypsinogen A. Reprinted with permission
from ref. 18
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A) Diagram of the set-up for the dual detection pressure-based technique for assessing
protein adsoption. B) Pressure-driven propagation of 5.3 µM chromeo-labeled conalbumin
detected at 10 and 40 cm. Better protection against adsorption can be seen in both the
capillary coated with CElixir dynamic modifier and the capillary with a permanently
adsorbed PVA coating. Reprinted with permission from ref. 34
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A) Step-by-step overview of the Simon™ operational procedure. B) Comparison between
the manual Western and Simon™ for duplicate runs of three proteins. Experimental details
for protein and antibody conditions in ref. 31. Reprinted with permission from ref. 42
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Schematic layout of the on-line multiple junction CIEF setup; the six-port injector is shown
in the sample-loop loading position. Reprinted with permission from ref. 60
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Schematic of the Nanopro three-step process . 1) Separation by CIEF, 2) immobilization of
the antibody to the capillary wall, 3) detection with secondary antibody by
chemiluminescence. Reprinted with permission from ref. 65
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A) Diagram of the separation of four proteins without and B) with the pseudostationary
phase effect of the polyamidoamine (PAMAM)-grafted silica nanoparticles (SNP).
Reprinted with permission from ref. 68
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Diagrams of four CE-ESI-MS interfaces. A) Sheath-flow, B) Moini and Whitt sheathless
flow, C) Chen junction-at-the-tip, D) sheathless interface for CITP/CZE-nanoESI-MS.
Reprinted/adapted with permission from ref. 89, 94, 102, 62 respectively
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(A) Microchip overview. Samples are loaded in different sample reservoirs (S). Samples are
injected by floating the buffer reservoir (BR) and sample waste (SW) with voltage applied
between the desired sample reservoir and the Al block at the exit. During separation, flow
from the sample reservoir is gated to the sample waste reservoir (SW) using the voltages as
shown. During these operations, other sample reservoirs are floating. Sieving media is
pumped through the sheath channels to give stable current. Channel lengths are indicated by
double arrow lines and direction of flow during separation is indicated by solid, single
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arrows. B) Size-dependent separation of FITC-labeled protein ladder in microchips.
Detection window was set at the end of separation channel, 300 µm away from the chip
outlet. Electric field during separation was 240 V/cm. C) Relationship of MW to migration
time. Reprinted with permission from ref. 140
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Schematic of the hybrid capillary LC microchip CE-ESI experimental setup. The orange line
represents a transfer capillary connecting the LC column to the microfluidic device. The
dashed green lines represent electrical connections between the high voltage power supply
and the microfluidic reservoirs. Reprinted with permission from ref. 146
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